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Introduction
!
Esophageal strictures are common, though the
use of proton pump inhibitors has greatly reduced
the incidence of benign peptic strictures [1,2].
Strictures can occur secondary to gastroesopha-
geal reflux disease (GORD) and caustic ingestion
and after esophageal surgery or radiotherapy [3].
Management of esophageal strictures is a clinical
challenge. Currently the practice in most units is
recurrent dilatation for benign peptic strictures
with balloon or bougies. Even though 80% to 90%
of patients will initially respond to dilatation, a
majority of them will need more than 1 session
and fewer than 10% will experience refractory or
recurrent strictures, with repeated dilatation hav-
ing only minimal effect. Multiple dilatation ses-
sions expose the patient to cumulative risks asso-
ciated with the procedures and carry a small,
nevertheless significant risk of perforation and
even death [3]. Other therapeutic modalities,
such as intralesional injection of steroids, have
been assessed with encouraging results [4], how-
ever, multiple sessions typically are needed and
long strictures are difficult to treat. In addition to
these, the optimal injection technique as well as
the frequency and dose of steroids to be used are
yet to be established [5]. Removable plastic (SEPS)
or fully covered metal self-expanding stents
(FCSEMS) have also been tried, but initial positive
results were not replicated [6,7] and a recent
meta-analysis reported significant migration
rates and mediocre success rates overall [8].
Esophageal malignancies are usually associated
with stricture disease and self-expanding metal
stent (SEMS) placement is a well-established pal-
liative modality. However, in patients who are
candidates for neoadjuvant chemo-radiotherapy
(CRT) prior to surgery or radical radiotherapy, in-
sertion of uncovered or partially covered metal
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Background and study aims: Biodegradable (BD)
esophageal stents were recently developed main-
ly for refractory benign strictures, but experience
and available literature are limited.
Patients and methods: This was a retrospective
observational study. All patients who had BD
stents inserted due to refractory benign esopha-
geal strictures or malignant strictures, or were
awaiting radical radiotherapy/chemotherapy or
neo-adjuvant therapy and esophagectomy be-
tween March 2011 and July 2015 were included.
Results: Stent placement was successful in all pa-
tients. Ten patients with benign strictures (3
male, median age 80.5 years, IQR: 68.75–89.5)
were followed-up for a median of 171.5 weeks
(IQR: 24–177.25). The interval between dilata-
tions prior to the first BD stent placement (medi-
an: 34.25 days, IQR: 23.06–48.29) was signifi-
cantly shorter than the interval between the first
BD stent placement and the first intervention re-
quired (median: 149.5 days, IQR: 94.25–209.5)
and this difference was statistically significant
(P=0.012). Ten patients with esophageal cancer
(8 male, median age: 69 years, IQR: 59.25–80.75)
were included and they were followed up for a
median of 36weeks (IQR: 26–58). Only 1 comple-
ted radical radiotherapy successfully, but devel-
oped refractory post-radiotherapy stricture. No
one proceeded to esophagectomy and 50% re-
quired a self-expanding metal stent (SEMS) at a
median of 134 days (IQR: 100–263) following
stent placement.
Conclusions: BD stents were successfully de-
ployed in both benign and malignant strictures.
They offered a prolonged dilatation-free interval
in benign strictures, yet in the majority of pa-
tients, strictures recurred. In malignant strictures,
stent patency was similar to that of benign stric-
tures, which suggests a potential value in ensur-
ing adequate oral intake during oncologic ther-
apy. In our cohort, however, use of stents did not
contribute to improved outcome.
stents is associated with a number of problems such as tumor in-
growth, stent displacement, inability to remove and difficulties
posed during surgery and radiotherapy planning [9–12]. There-
fore, FCSEMS as well as SEPS have been used, in view of their abil-
ity to be removed when needed. Results were inconsistent, but
generally suboptimal, with most studies showing significant
stent migration rates [13].
There is a need to develop a new strategy to improve outcomes
for both benign and malignant indications. Stents made of biode-
gradable material were first developed and tried in 1997 [14], but
it was only in 2008 that a new biodegradable (BD) stent, the SX
Ella BD Stent (Ella- CS, Hradec Kralove, Czech Republic), was de-
veloped and became available commercially for clinical use.
Those stents biodegrade after 11 to 12 weeks, thus making them
appealing alternatives for both benign esophageal strictures and
malignant ones, as a bridge to more radical interventions [15].
The aim of this study was to retrospectively evaluate the clinical
effectiveness and safety of the SX Ella BD stent in benign and ma-
lignant strictures.
Patients and methods
!
This was a retrospective, single-center study, in a university hos-
pital and tertiary referral center in Scotland, UK. The hospital’s
electronic records database, as well as the endoscopy reports
electronic database, were reviewed for all patients who had the
stent inserted from March 2011 until July 2015.We started to
use the biodegradable stents in 2011 for benign strictures. In
those cases, malignancy was excluded after multiple biopsies.
The use of the stents was later extended to malignant strictures.
Ethics
This study was conducted in accordance with UK research ethics
guidelines. After review by the local ethics committee, further
specific ethical review and approval were not required, as the
study was considered a retrospective clinical audit work, using
data already obtained as a part of regular patient care.
Patient cohort for stent insertion
All patients who had the stent inserted from March 2011 to July
2015 were included in this retrospective study. The end of fol-
low-up period for each patient was July 2015 or time of death.
Patients were selected for insertion of the BD stent on an individ-
ual basis after discussing the risks and benefits and obtaining an
informed consent. Dysphagia was the main symptom. In our se-
rieswe included a number of recurring strictures (>3 consecutive
dilatations) but in such cases, patients were keen to consider al-
ternative options rather than continue with further dilatations
and a number of refractory strictures when a lumen of 15mm
after at least 5 dilatations could not be maintained. All the cases
represent real-life clinical data. Because this was not a strict pro-
tocol-driven prospective study, patient preferences as well as lo-
gistic restrictions occasionally influenced the timing and number
of procedures. Patients with benign esophageal strictures were
initially selected, as they were considered to represent the group
whowould mainly benefit from this newmodality and for whom
most evidence was available. All patients in the benign group had
malignancy excluded on multiple biopsies.
Whenmore experiencewas gained locally and after reports of its
use in malignant strictures became available, this modality was
offered to a select group of patients with malignant strictures fol-
lowing discussion at the regional multidisciplinary upper gastro-
intestinal cancer case conference and with the patients’ agree-
ment to consider this interim treatment option. In such cases
the decision to insert a BD-stent was made to give the opportu-
nity to assess the initial response to chemotherapy or radiother-
apy before the final management decision. Such patients were fit
but borderline candidates for radical therapies due to disease
staging and in most cases were of a younger age group. It is of
note that the use of BD-Stent is licensed only for benign strictures
and its use in the setting of malignancy is “off-label.”
The stent
The biodegradable stent available as the SX Ella BD Stent, Ella-
CS (Hradec Kralove, Czech Republic) is made of woven polydiox-
anone monofilament and available in lengths from 60mm to
135mm. It is radiolucent but has radiopaque markers at both
ends and in the middle. The material degrades by hydrolysis,
which is accelerated by low pH. The mechanical strength lasts
for about 3 weeks and it begins to disintegrate in 11 to 12 weeks.
Pre-dilation of the stricture just prior to insertion of the stent is
recommended. The stent needs to be assembled and loaded onto
the delivery system prior to insertion. It has a distal release
mechanism.
All procedures were undertaken by endoscopists with experi-
ence in esophageal stenting and all procedures took place at the
radiology suite, under fluoroscopic guidance. Standard doses of
sedation and analgesia (midazolam and fentanyl) were used
along with topical anesthesia. Patients were in the left lateral
position. As a rule, all patients had their stricture dilated to 11 to
12mm with a controlled radial expansion (CRE) balloon or
Savary-Gilliard dilator prior to stent insertion. This was per the
recommendation from the manufacturer. In order to facilitate ac-
curate stent placement, 1mL to 2mL of contrast was injected
submucosally, using a sclerotherapy needle just above the stric-
ture, and under fluoroscopic guidance, the point of injection
was aligned to the markers on the proximal end of the stent. Cor-
rect positioning was checked endoscopically.
Statistical analysis
Statistical analysis was conducted using SPSS 21.0 (IBM corp.,
Version 21.0, Armonk, NY, USA). Data are presented as frequen-
cies for categorical variables and as median and interquartile
range (IQR) for continuous variables. The mean time between di-
latations, in days, was calculated as the time interval between the
first dilatation and the first BD stent placement/number of dilata-
tion prior to BD placement. This was compared to the time inter-
val between the BD stent insertion and the first intervention (di-
latation or further stent placement) required after the first BD
stent, using Wilcoxon signed rank test. A P value less than 0.05
was considered as statistically significant.
Results
!
Benign strictures
Patient characteristics and outcomes
A total of 17 stents were inserted in 10 patients with benign stric-
tures. There were 3 males and 7 females ranging in age from 54
years to 101 years (median: 80.5 years, IQR: 68.75–89.5). The
median follow-up period was 171.5 weeks (IQR: 24–177.25).
Eight of the patients had peptic strictures, while 1 had a benign
stricture following radical radiotherapy for esophageal squamous
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carcinoma and another had anastomotic strictures, following
esophagectomy for esophageal cancer. The length of the stric-
tures ranged from 0.5cm to 8cm (median: 4cm). Five patients
had 2 BD stents each inserted over the course of the study and 1
patient had 3 stents. The remaining 4 patients had a single BD
stent placed. Of 10 patients, 7 were still alive at the end of fol-
low-up.Two died at 188 and 65 days after stent placement
respectively, for reasons not related to the procedure, without
having any further intervention performed in the meantime. An
85-year-old patient died 1 year after BD stent placement and had
required 3 dilatations and an additional BD stent following that.
The indications for stent insertion, number of BD stents, and need
for further interventions and final outcome are indicated in●" Ta-
ble1.
All benign strictures were dilated using a CRE balloon at the time
of stent insertion, with the exception of a single patient in whom
a Savary-Gilliard (SG) dilator was used. Stent insertion was tech-
nically successful in all cases.
There was 1 serious complication in a patient who was admitted
with sepsis post-stent insertion, which was successfully treated.
A few minor complications were also recorded. One patient had
mild pain post-insertion and 2 food bolus obstructions a few
weeks after stent insertion that were relieved endoscopically. In
one of them the lumen was actually patent by the time the
endoscopy was done.
Overall, all surviving patients required repeat procedures. Two of
them were treated with metal stents due to recurrent dysphagia
despite repeat BD stent placement. They remained symptomatic
however, and required further dilatations, even though at less
frequent intervals.
Effect of BD stent placement in the need for subsequent
interventions
Two of the 10 patients who received BD stents for benign stric-
tures died without receiving further treatment following the
procedure, as mentioned above. Among the remaining 8 patients,
the interval between dilatations prior to the first BD stent place-
ment varied between 12 days and 67 days (median: 34.25, IQR:
23.06–48.29). The interval between the first BD stent placement
and the first intervention required (further BD/metal stent place-
ment or dilatation) ranged between 60 days and 244 days (medi-
an: 149.5, IQR: 94.25–209.5). The difference between those 2 in-
tervals was statistically significant (P=0.012). The 6 patients who
required more than one stent had equally prolonged periods
without intervention (median interval of first intervention after
the placement of the second BD stent: 199.5 days, IQR: 118.5–
330.25)
Malignant strictures
Ten patients had 11 BD stents inserted for malignant strictures.
Median follow-up was 36 weeks (IQR: 26–58). Those patients
were planned to have radical chemotherapy and/or radiotherapy
with curative intent or alternatively to receive neoadjuvant treat-
ment awaiting esophagectomy. None of them had previous dila-
tation or stenting. All but 1 had dilatation to 10mm to 11mm at
the time of stenting. The length of stricture varied between 2cm
and 9cm (median: 6cm). Stents measuring 6cm and 13.5cm in
length were inserted. Three patients experienced mild to moder-
ate pain post-procedure, lasting for less than 48 hours. There was
1 case of food bolus obstruction a few weeks after insertion,
which was secondary to tumor in-growth and required plasma
coagulation (APC).
Five of 10 patients had metal stents inserted between 77 days
and 308 days following BD stent placement (median: 134 days,
IQR: 100–263). This was due to tumor progression. The median
interval between BD stent placement and death or SEMS place-
ment, previously termed “stent patency period” [16] was 204
days (IQR: 131.25–279.5). Despite treatment with chemotherapy
and/or radiotherapy, no patient managed to proceed to esopha-
gectomy except 1 patient who had an attempted esophagectomy,
Table 1 Benign strictures. Patient characteristics and follow up including the number of pre- and post BD stent placement dilatations, the mean interval be-
tween dilatation prior to BD stent placement, the mean interval for repeat intervention following BD stent placement, number of BD stents used in each patient
and overall clinical course of each patient.
Patient Age Gender Stricture
cause
pre-BD stent
dilatations
Post-BD
stent dilata-
tions
Mean interval
(days) between
dilatations prior
to BD stent
Interval be-
tween BD stent
and 1st inter-
vention
Total
number
of BD
stents
Follow-up after
1st BD stent
1 71 Female Peptic 3 4 67 190 2 2nd BD and SEMS
and dilatations
2 91 Female Peptic 12 0 36 N/A 1 No further inter-
vention-deceased
3 54 Male Peptic 8 7 33 244 2 2nd BD stent and
dilatations
4 101 Female Peptic 7 5 45 216 2 2nd BD stent and
dilatations
5 72 Female Peptic 4 4 58 89 2 2nd BD and SEMS
and dilatations
6 81 Male Peptic 3 35 12 60 1 Repeat dilatations
7 80 Female Post-radio-
therapy
8 7 21 169 3 2 more BD stents
and dilatations
8 85 Female Peptic 3 3 36 110 2 Repeat dilatations-
Deceased-
9 89 Female Peptic 6 1 24 130 1 Repeat dilatation
10 62 Male post-esopha-
gectomy
4 0 24 N/A 1 No further inter-
vention-Deceased
BD, biodegradable; N/A, non-applicable; SEMS, self-expanding metal stent.
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but tumor was considered unresectable at surgery and the proce-
dure was abandoned.
Poor progression to surgery was either due to suboptimal re-
sponse to neoadjuvant chemoradiotherapy, intolerance or devel-
opment of complications. Only 1 patient was still alive at the end
of the follow-up period. Overall survival following the BD stent
placement ranged between 19 weeks and 98 weeks (median 34
weeks, IQR: 25–56). A 76-year-old, female patient who received
radical radiotherapy developed post-radiotherapy esophageal
stricture despite the placement of a BD stent prior to the therapy.
She received a second BD stent a year later, but it was not effec-
tive. She required 2 dilatations in the meantime but her stricture
proved to be refractory. Due to poor general health and personal
preference, she had a nasogastric feeding tube placed, which was
retained until her death 21 months after the initial BD stent
placement. There was no documented disease recurrence until
her death. Patient details, including need for SEMS and BD stent
patency duration and survival, are presented in●" Table2.
Discussion
!
Although BD stents are currently licensed for benign strictures,
there have been studies assessing their effect in the context of
malignant strictures. In this paper, although we report our ex-
perience in both patient groups, data analysis interpretation and
discussion of the results with regard to benign and malignant
strictures were done separately.
Refractory esophageal strictures comprise a significant clinical
challenge. As an alternative to repeated dilatations, it has been
proposed that placement of a stent could lead to prolonged peri-
ods between dilatations and remodeling of the stricture, thus im-
proving the clinical outcome. Clinical trials assessing the efficacy
of FCSEMS and SEPS had suboptimal long-term outcomes. A re-
cent meta-analysis [8] regarding the treatment efficacy of
FCSEMS, SEPS and BD stents in refractory benign strictures, found
an overall clinical success rate of 40.5% when all treatment mod-
alities were considered. The differences in the success rates be-
tween the various modalities were not statistically significant.
Table 2 Malignant strictures. Data regarding patient characteristics, BD stent patency duration, need for SEMS and survival
Pa-
tient
Age Gen-
der
Tumor
location
Histology Stage Final treatment decision Need
for
SEMS
BD stent
patency
duration
(days)
Time
to
SEMS
(days)
Death Survival post-
BD stent
placement
(days)
1 47 male Lower Adenocar-
cinoma
T2N0M1 Palliative (metastasis
seen in PET scan)
yes 134 134 yes 357
2 68 male Lower Squamous T3N1M0 Neoadjuvant chemother-
apy- attempted esopha-
gectomy but found to be
unresectable then re-
ferred for radiotherapy
following BD
no 189 N/A yes 189
3 80 female Lower Squamous T3N0M0 Radical Rx-decision to
continue with palliation
following BD-stent inser-
tion
no 690 N/A yes 690
4 60 male Lower Squamous EUS:T4N2Mx
PET: T3N1M0
Chemotherapy with very
low success potential in
view of considering re-
section if disease re-
sponded, but disease
progressed
no 239 N/A yes 239
5 83 male Lower Adenocar-
cinoma
TxNxM0 Palliation yes 77 77 yes 133
6 70 male Upper Squamous T4N1M0 Palliation no 167 N/A yes 167
7 57 male Lower Adenocar-
cinoma
T3N0M0 Initial plan to perform
esophagectomy but this
was postponed due to
bleeding. Had BD-stent
and Rx in view of reat-
tempting surgery but
only partial response-
palliative treatment
yes 219 219 yes 427
8 83 male Lower Adenocar-
cinoma
T3N2M0 Initial radical Rx but con-
tinued as palliative in
view of age and co-mor-
bidities
yes 123 123 yes 31
9 66 male Lower Adenocar-
cinoma
T3N2M0 Neoadjuvant chemother-
apy but suboptimal re-
sponse- palliative treat-
ment
yes 308 308 no N/A
10 76 female Middle Squamous T3N0M0 Radical Rx no 270 N/A yes 38
BD, Biodegradable; N/A, non-applicable; Rx, Radiotherapy; SEMS, self-expanding metal stent
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BD stent success ratewas 32.9%. No statistically significant differ-
ences were found in rates of migration (overall 28.6%, BD-stent
15.3%) or adverse events (AEs) (overall 20.6%, BD-stents 21.9%).
The most common AE was chest pain. It is important to note
that this meta-analysis detected significant heterogeneity be-
tween studies and this was more prominent in FCSEMS studies.
The overall clinical success for benign strictures in this study, de-
fined as no need for further intervention until the end of follow-
up period, was 20%. Two patients remained asymptomatic fol-
lowing the stent placement. Both died at 26 weeks and 9 weeks,
respectively, following the BD stent placement, for reasons unre-
lated to it. Those results are similar to those previously reported,
but it is important to note that none of the patients still alive at
the end of the study period was asymptomatic. The serious com-
plication rate was relatively low (5.3%) and the migration rate
was 0%. No mortality attributed to stent insertion was seen.
Those figures are encouraging with regard to the safety of this
modality. In our cohort, chest pain was not a major problem and
patients respondedwell to analgesia. In our experience, adequate
dilatation of the stricture to at least 11mm prior to BD stent in-
sertion is important. Even though the retrospective nature of the
study could potentially result in under-reporting of minor chest
pain episodes, severe complications requiring prolonged hospi-
talization stent removal or AEs such as bleedings or perforations
would have being clearly documented in the patient records.
A previous study showed a decrease in the frequency of dilata-
tions required following BD stent placement [17]. It was not pos-
sible to assess that in our series because only 4 patients had a sin-
gle BD stent and of them, only 2 required further dilatations. The
remaining patients had 2 or 3 stents placed. Nevertheless, follow-
ing the placement of the initial BD stent, patients experienced a
median of 149.5 days (21 weeks) of improved symptoms, not re-
quiring further intervention. Interestingly, this period was signif-
icantly longer than the expected lifetime of the BD stent (12
weeks). Even though the patients eventually required repeat dila-
tations, the intervention-free period was significantly longer
compared to the previous median interval between dilatations
(5 weeks). This gave the patients the opportunity to temporarily
avoid the unpleasant experience of repeat dilatations, as pointed
out in previous reports [18]. This applied also to the patients who
subsequently had more than 1 additional BD stent.
Dysphagia caused by malignant strictures is a totally different
problem altogether. Several factors need to be considered in the
management of these patients.
Results of 2 prospective and 1 retrospective trials are now avail-
able. Krokidis et al. [16] prospectively studied 11 patients with
malignant strictures. Early complication rates were significant
(27.2%) and 2 out of 11 patients died due to complications related
to tracheoesophageal fistula formation. Only 3 patients had a pa-
tent stent at the end of the follow-up period and were supposed
to complete neoadjuvant chemotherapy prior to esophagectomy.
Griffiths et al. [19] included 16 patients with malignant stric-
tures. Only 1 was waiting for surgery, 4 months after BD stent
placement. There were 3 patients that progressed to attempted
resection, but their tumors were found to be unresectable. The
rest showed disease progression or were deemed unfit for sur-
gery. Eight required SEMS insertion and 2 required nasogastric
tube placement. Similar low rates of progression to surgery in
the neoadjuvant setting have been reported previously for
FCSEMS [20]. Finally, Van der Berg et al. [21] prospectively stud-
ied 10 patients with malignant esophageal strictures who receiv-
ed BD stents while undergoing neoadjuvant chemoradiotherapy.
They reported 30-day morbidity and overall AE rates of 60% and
70%, respectively. Most of those AEs were related to retrosternal
pain, sometimes lasting for more than 10 days, while 1 case of
stent obstruction due to necrotic tissue was also reported. No
stent migration was noted. At the end of follow-up, 6 of 10 pa-
tients underwent esophagectomy. Despite this relatively positive
outcome, 9 of 10 patients experienced weight loss at the end of
follow-up and the authors raised concerns that the pain might
have led to reduced eating.
In line with Griffiths et al. [19], we also documented a disap-
pointingly low rate of progression to surgery (0%). This was a se-
lective group of patients in the context of a retrospective study
who were considered fit for radical therapies but they were bor-
derline with regard to their potential for curative interventions.
Half of our patients eventually needed a SEMS and only 1 patient
receiving radiotherapy seemed to be disease-free at the time of
her death. Nevertheless, she had developed a refractory post-
radiotherapy stricture, despite placement of a BD stent. On the
positive side, BD stents remained patent not needing further in-
tervention for a median of 204 days, significantly more than the
expected lifespan of the stent itself.
In accordance with Van den Berg et al. [21], post-insertion chest
painwas themost common complication in our series, affecting 3
out of 10 patients. Post-procedural pain is most likely related to
the increased axial force [22], the relatively large diameter of
these stents, and the need for dilatation prior to stent deploy-
ment. However, in contrast to the aforementioned study, none
of our patients experienced significant pain requiring analgesia
for more than 48 hours. This may be related to the fact that,
with a single exception, all our patients had dilatation to 10mm
to 11mm. In contrast, patients in the Nan den Berg et al. study
only received dilatation if the stricture was not passable with
the pediatric scope, and when dilated, this was done to 10mm
at most. Furthermore, differences regarding the severity of base-
line dysphagia and/or tumor characteristics may have also con-
tributed to this discrepancy. We did not document any case of
stent migration in the malignant group of this study and there
was no 30-daymortality or any severe procedure-related compli-
cations, in line with Van den Berg et al. Tissue ingrowth was
noted in 2 patients and in 1 patient was severe enough to cause
food bolus obstruction. Endoscopic intervention in the form of
APC treatment and subsequent SEMS placement were required.
Generally the tissue reaction was mild and actually helped an-
chor the stent and prevent migration.
This study has certain limitations. First, it is retrospective and
lacks a control group.As such, there is unavoidable selection
bias. Stent insertion was determined on an individual basis not
using the Kochman criteria [23]but rather, using a realistic ap-
proach, taking into consideration logistic parameters and patient
preference. Patients with benign refractory esophageal strictures
were generally those who had multiple failed dilatations and
were therefore the most difficult to treat in any case. We did not
evaluate pre- and post-intervention symptom scores or quality-
of-life metrics. Nevertheless, despite this not being a comparative
study, the number of patients was comparable to previous stud-
ies, while the follow-up periodwas probably the longest reported
to date, for both benign and malignant indications.
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Conclusions
!
Application of BD stents is relatively safe and the main complica-
tion is retrosternal pain, which tends to be moderate. Biodegrad-
able stents in benign refractory esophageal strictures seem to
provide a dilatation-free interval for patients which can be signif-
icantly longer than the expected life expectancy of the stent.
However, in the long term, the vast majority of patients require
repeat interventions. The role of repeated BD stent placements
should be assessed prospectively and compared to repeat dilata-
tions using a formal predefined study protocol.
Regarding malignant strictures, although the period of stent pa-
tency was similar to that for benign strictures, patient outcomes
were not encouraging. Similarly discouraging results have been
reported for other stenting options in the neoadjuvant setting
[13]. Therefore, although BD stents may have a role in patients
with esophageal cancer to improve oral intake without the need
for nasogastric feeding during oncological therapy, at present,
there are no data to support their use in that population to im-
prove outcomes. Further studies are needed to prospectively as-
sess the use of BD stents in esophageal malignancy.
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